57 phenotypes from 3 alleles in 11 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Slc2a4tm1Abel/Slc2a4+ Tg(Ckmm-cre)5Khn/0 involves: 129S4/SvJae * FVB	decreased intestinal glucose absorption	J:110773
	decreased muscle cell glucose uptake	J:110773
Slc2a4tm1Abel/Slc2a4tm1Abel Tg(Ckmm-cre)5Khn/? involves: 129/Sv * C57BL/6	abnormal circulating glucose level	J:75418
	abnormal glucose tolerance	J:75418
	abnormal lipid homeostasis	J:75418
	abnormal lipid level	J:75418
	abnormal muscle physiology	J:75418
	decreased body weight	J:75418
	decreased fatty acids level	J:75418
	decreased muscle cell glucose uptake	J:75418
	decreased triglyceride level	J:75418
	hyperglycemia	J:75418
	increased liver glycogen level	J:75418
	insulin resistance	J:75418
	normal muscle phenotype	J:75418
Slc2a4tm1Abel/Slc2a4tm1Abel Tg(Ckmm-cre)5Khn/0 involves: 129S4/SvJae * FVB	abnormal glucose homeostasis	J:110773
	abnormal lipid homeostasis	J:110773
	decreased adipocyte glucose uptake	J:110773
	decreased intestinal glucose absorption	J:110773
	decreased muscle cell glucose uptake	J:110773
	increased adipocyte glucose uptake	J:110773
	increased circulating glucose level	J:110773
	increased circulating insulin level	J:110773
Slc2a4tm1Abel/Slc2a4tm1Abel Tg(Fabp4-cre)1Abel/? involves: 129S4/SvJae * FVB	abnormal glucose homeostasis	J:67292
	abnormal glucose tolerance	J:67292
	abnormal glycogen homeostasis	J:67292
	insulin resistance	J:67292
Slc2a4tm1Abel/Slc2a4tm1Abel Tg(Myhca-cre)1Abel/? involves: 129S4/SvJae * C57BL/6 * FVB	abnormal cardiovascular system physiology	J:108830
	abnormal response to cardiac infarction	J:108830
	decreased cardiac muscle cell glucose uptake	J:108830
	decreased left ventricle systolic pressure	J:108830
	increased cardiac muscle cell glucose uptake	J:108830
	increased cardiac muscle glycogen level	J:108830
Slc2a4tm1Abel/Slc2a4tm1Abel Tg(Myhca-cre)1Abel/? involves: 129S4/SvJae * FVB	abnormal cardiovascular system physiology	J:59054
	abnormal glucose homeostasis	J:59054
	abnormal glucose tolerance	J:59054
	abnormal heart morphology	J:59054
	abnormal myocardium layer morphology	J:59054
	abnormal nervous system physiology	J:59054
	cardiac hypertrophy	J:59054
	decreased body weight	J:59054
	decreased cardiac muscle cell glucose uptake	J:59054
	increased heart weight	J:59054
Slc2a4tm1Jdz/Slc2a4tm1Jdz involves: 129S1/Sv * C57BL/6	decreased adipocyte glucose uptake	J:123335
	decreased muscle cell glucose uptake	J:123335
	increased circulating glucose level	J:123335
	increased circulating insulin level	J:123335
	increased heart weight	J:123335
Slc2a4tm1Jdz/Slc2a4tm1Jdz Tg(ACTA1-cre)1Jdz/0 involves: 129S1/Sv * C57BL/6 * CBA	cardiac hypertrophy	J:123335
	cardiac interstitial fibrosis	J:123335
	decreased adipocyte glucose uptake	J:123335
	decreased muscle cell glucose uptake	J:123335
	increased adipocyte glucose uptake	J:123335
	increased cardiac muscle cell glucose uptake	J:123335
	increased circulating glucose level	J:123335
	increased circulating insulin level	J:123335
	increased heart weight	J:123335
	increased muscle cell glucose uptake	J:123335
	thick ventricular wall	J:123335
Slc2a4tm1Mch/Slc2a4+ involves: 129/Sv * C57BL/6 * SJL	impaired glucose tolerance	J:97234
	increased insulin secretion	J:97234
	pancreatic islet hyperplasia	J:97234
Slc2a4tm1Mch/Slc2a4+ involves: 129/Sv * C57BL/6J * CD-1 * SJL	abnormal glucose homeostasis	J:43935
	abnormal glycogen homeostasis	J:43935
	cardiac hypertrophy	J:43650
	decreased muscle cell glucose uptake	J:43650, J:43935
	dystrophic cardiac calcinosis	J:43650
	heart inflammation	J:43650
	hepatic steatosis	J:43650
	normal homeostasis/metabolism phenotype	J:43650, J:43935
	hyperglycemia	J:43650
	hypertension	J:43650
	increased circulating insulin level	J:43650, J:43935
	increased fat cell size	J:43650
	insulin resistance	J:43650, J:43935
	macrovesicular hepatic steatosis	J:43650
	myocardium necrosis	J:43650
Slc2a4tm1Mch/Slc2a4tm1Mch involves: 129/Sv * C57BL/6 * C57BL/6J * CD-1 * SJL	abnormal circulating glucose level	J:49328
	abnormal muscle physiology	J:49328
	cardiac hypertrophy	J:49328
	decreased circulating free fatty acids level	J:49328
	decreased circulating ketone body level	J:49328
	decreased gonadal fat pad weight	J:49328
	decreased total body fat amount	J:49328
	normal homeostasis/metabolism phenotype	J:49328
	increased circulating insulin level	J:49328
	increased heart weight	J:49328
	insulin resistance	J:49328
	postnatal growth retardation	J:49328
	premature death	J:49328
Slc2a4tm1Mch/Slc2a4tm1Mch involves: 129/Sv * C57BL/6 * C57BL/6J * SJL	abnormal skeletal muscle fiber type ratio	J:75600
	cardiac hypertrophy	J:75600
	decreased body mass index	J:75600
	decreased skeletal muscle glycogen level	J:75600
	decreased skeletal muscle mass	J:75600
	impaired skeletal muscle contractility	J:75600
	increased muscle fatigability	J:75600
Slc2a4tm1Mch/Slc2a4tm1Mch involves: 129/Sv * C57BL/6J * SJL	cardiac hypertrophy	J:107849
	cardiac interstitial fibrosis	J:107849
	thick ventricular wall	J:107849
Slc2a4tm1Mch/Slc2a4tm1Mch involves: C57BL/6 * CBA	abnormal glucose homeostasis	J:69914